Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference19 articles.
1. Potential factors affecting adherence with HIV therapy.;Mehta;AIDS,1997
2. A lopinavirritonavir-based once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 weeks.;Molina;AIDS Res Hum Retroviruses,2007
3. Multistep inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.;Rabi;J Clin Investig,2013
4. A once-daily lopinavirritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.;Gathe;J Acquir Immune Defic Syndr,2009
5. A once-daily lopinavirritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.;Johnson;J Acquir Immune Defic Syndr,2006
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety of Antiretroviral Therapy in the Treatment of HIV/AIDS in Children: Systematic Review and Meta-analysis;Aids Reviews;2022-01-11
2. Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products;The AAPS Journal;2021-04-21
3. Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2;Journal of the Pediatric Infectious Diseases Society;2020-04-22
4. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV;Therapeutic Drug Monitoring;2019-08
5. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice;Pediatric Infectious Disease Journal;2017-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3